• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Beth Israel Deaconess Medical Center - Developmental Therapeutics Review - Q4 2010 Product Image

Beth Israel Deaconess Medical Center - Developmental Therapeutics Review - Q4 2010

  • ID: 1464037
  • December 2010
  • Region: Israel
  • 99 pages
  • Global Markets Direct

Beth Israel Deaconess Medical Center – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Beth Israel Deaconess Medical Center – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by Beth Israel Deaconess Medical Center.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products READ MORE >



List of Tables
List of Figures
Beth Israel Deaconess Medical Center Snapshot
Beth Israel Deaconess Medical Center Overview
Key Information
Key Facts
Beth Israel Deaconess Medical Center – Research and Development Overview
Key Therapeutic Areas
Beth Israel Deaconess Medical Center – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Beth Israel Deaconess Medical Center – Pipeline Products Glance
Beth Israel Deaconess Medical Center – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Beth Israel Deaconess Medical Center Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Beth Israel Deaconess Medical Center–Early Stage Pipeline Products
Discovery Products/Combination Treatment Modalities
Beth Israel Deaconess Medical Center – Drug Profiles
Amiodarone
Product Description
Mechanism of Action
R&D Progress
Enoxaparin
Product Description
Mechanism of Action
R&D Progress
Gabitril
Product Description
Mechanism of Action
R&D Progress
Simvastatin
Product Description
Mechanism of Action
R&D Progress
Aldesleukin for Renal cell carcinoma (Beth Israel Deaconess Medical Center)
Product Description
Mechanism of Action
R&D Progress
Avastin
Product Description
Mechanism of Action
R&D Progress
Avastin + Temsirolimus
Product Description
Mechanism of Action
R&D Progress
CT-011 + Dendritic Cell Fusion Vaccine + Stem Cell Transplantation
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Fludarabine + Cyclosporine + Campath-1H + GM-CSF
Product Description
Mechanism of Action
R&D Progress
Daclizumab + Aldesleukin
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Tumor Fusion Vaccine + Granulocyte Macrophage Colony Stimulating Factor
Product Description
Mechanism of Action
R&D Progress
docetaxel
Product Description
Mechanism of Action
R&D Progress
donepezil
Product Description
Mechanism of Action
R&D Progress
Electrofusion DC Vaccine
Product Description
Mechanism of Action
R&D Progress
Everolimus
Product Description
Mechanism of Action
R&D Progress
Faslodex
Product Description
Mechanism of Action
R&D Progress
GM-CSF + Dendritic Cell Tumor Fusion Vaccine + imiquimod
Product Description
Mechanism of Action
R&D Progress
GM-CSF + Dendritic Cell-Tumor Fusion Vaccine + Imiquimod
Product Description
Mechanism of Action
R&D Progress
Insulin Sensitizer + Leptin
Product Description
Mechanism of Action
R&D Progress
Intranasal Insulin
Product Description
Mechanism of Action
R&D Progress
Ketaconazole + Hydrocortisone + Dutasteride
Product Description
Mechanism of Action
R&D Progress
Ketamine
Product Description
Mechanism of Action
R&D Progress
Ketoconazole + Hydrocortisone + Dutasteride
Product Description
Mechanism of Action
R&D Progress
Leptin
Product Description
Mechanism of Action
R&D Progress
RAD001+ Trastuzumab
Product Description
Mechanism of Action
R&D Progress
rituximab + yttrium Y 90 ibritumomab tiuxetan
Product Description
Mechanism of Action
R&D Progress
Sorafenib + Radiofrequency Ablation
Product Description
Mechanism of Action
R&D Progress
Sorafenib for Hepatocellular Carcinoma (Beth Israel Deaconess Medical Center)
Product Description
Mechanism of Action
R&D Progress
Testosterone + Arimidex
Product Description
Mechanism of Action
R&D Progress
Thiamine
Product Description
Mechanism of Action
R&D Progress
trastuzumab + carboplatin + carmustine + cisplatin + cyclophosphamide + thiotepa
Product Description
Mechanism of Action
R&D Progress
aldesleukin + interleukin-12
Product Description
Mechanism of Action
R&D Progress
Biological: in vitro expanded autologous invariant natural killer T cells|Drug: GM-CSF
Product Description
Mechanism of Action
R&D Progress
Bortezomib + Sorafenib
Product Description
Mechanism of Action
R&D Progress
carboplatin + docetaxel + gemcitabine hydrochloride
Product Description
Mechanism of Action
R&D Progress
Deferoxamine Mesylate
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Tumor Fusion Vaccine
Product Description
Mechanism of Action
R&D Progress
Docosahexaenoic acid
Product Description
Mechanism of Action
R&D Progress
HeFi-1
Product Description
Mechanism of Action
R&D Progress
Interleukin-12 + Interleukin-2
Product Description
Mechanism of Action
R&D Progress
Invariant Natural Killer Cells
Product Description
Mechanism of Action
R&D Progress
Plavix
Product Description
Mechanism of Action
R&D Progress
Recombinant Interleukin-12
Product Description
Mechanism of Action
R&D Progress
Thalidomide
Product Description
Mechanism of Action
R&D Progress
Therapeutic Autologous Lymphocytes
Product Description
Mechanism of Action
R&D Progress
Topotecan
Product Description
Mechanism of Action
R&D Progress
Trichuris suis ova
Product Description
Mechanism of Action
R&D Progress
RTEF-1
Product Description
Mechanism of Action
R&D Progress
Beth Israel Deaconess Medical Center – Pipeline Analysis
Beth Israel Deaconess Medical Center – Pipeline Products by Therapeutic Class
Beth Israel Deaconess Medical Center Pipeline Products By Target
Beth Israel Deaconess Medical Center – Pipeline Products by Route of Administration
Beth Israel Deaconess Medical Center – Pipeline Products by Molecule Type
Beth Israel Deaconess Medical Center – Recent Pipeline Updates
Beth Israel Deaconess Medical Center - Dormant Projects
Beth Israel Deaconess Medical Center – Locations And Subsidiaries
Head Office
Recent Developments
Oct 14, 2010: Cephalon Receives FDA Approval For Risk Evaluation And Mitigation Strategy For GABITRIL
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS